Thymosin Alpha-1

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally secreted by the thymus gland, where it plays a foundational role in T-lymphocyte (T-cell) maturation and immune regulation. Originally isolated by Allan Goldstein at George Washington University in the 1970s, the synthetic version (Zadaxin, thymalfasin) has been approved in over 35 countries for the treatment of hepatitis B, hepatitis C, and as an adjunct immune modulator in cancer therapy and vaccine augmentation. It is one of the most clinically validated immunomodulatory peptides available, with a substantial body of peer-reviewed research demonstrating its ability to amplify both innate and adaptive immune responses.

Thymosin Alpha-1 exerts its immunological effects primarily by activating Toll-like receptors (TLR-7 and TLR-9) on dendritic cells and macrophages — the sentinel cells of the innate immune system. This activation triggers a cascade that promotes the differentiation of naive T-lymphocytes into Th1 helper cells, which coordinate the cell-mediated immune response against intracellular pathogens (viruses, fungi, intracellular bacteria) and tumor cells. Tα1 also enhances natural killer (NK) cell activity, increases interferon-gamma (IFN-γ) production, and restores depressed thymic function. In patients with immune dysfunction — whether from age, illness, or immunosuppressive therapy — Tα1 effectively recalibrates T-cell populations toward functional homeostasis. In cancer research, it enhances the anti-tumor immune surveillance by augmenting dendritic cell cross-presentation of tumor antigens.

Thymosin Alpha-1 (thymalfasin/Zadaxin) is one of the most clinically validated immunomodulatory peptides. Multi-center Phase III clinical trials in hepatitis B (Asia-Pacific region, 1,000+ patients) demonstrated improved response rates and viral clearance. Phase II/III trials in hepatitis C showed enhanced interferon response. In Italy, clinical trials demonstrated improved outcomes in septic shock patients. The SciClone Pharmaceuticals IND for Zadaxin was accepted by the FDA. Studies in cancer patients showed enhanced response to chemotherapy and reduced infection rates. During the COVID-19 pandemic, retrospective studies in Italy and China showed significantly lower mortality in COVID-19 patients treated with Thymosin Alpha-1. It is approved and marketed in 35+ countries.

Immune Modulation Protocol: Thymosin Alpha-1 1.6 mg SC twice weekly for 6–8 weeks during periods of immune stress, illness, or recovery. Preventive Winter Protocol: 1.6 mg SC weekly for 12 weeks during autumn/winter. Combined Immune Stack: Thymosin Alpha-1 1.6 mg twice weekly + LL-37 100 mcg daily for broad-spectrum innate and adaptive immune support. Post-infection Recovery: 1.6 mg 3x weekly for 4 weeks to accelerate immune reconstitution.

Thymosin Alpha-1 is one of the safest peptides in clinical use. Mild injection site reactions (redness, mild swelling) are the most common reported effects. Mild fatigue or a flu-like feeling in the first few days of use is occasionally noted, consistent with immune activation. Because Tα1 promotes Th1 immune dominance, there is theoretical concern about exacerbating Th1-dominant autoimmune conditions (e.g., multiple sclerosis, type 1 diabetes, rheumatoid arthritis in certain phases) — it should be used cautiously in these populations. It is contraindicated in patients who have received or are receiving organ transplants due to its immune-activating effects that could promote rejection. Overall, the clinical safety record across thousands of patients in controlled trials is excellent.

Lyophilized Thymosin Alpha-1 (Zadaxin ampoules) should be stored at 2–8°C, protected from light. The commercially supplied solvent (typically sterile water in a separate ampoule) should also be refrigerated. Once reconstituted, administer immediately or within 8 hours when stored refrigerated. Research-grade lyophilized powder should be stored at -20°C for long-term stability and 2–8°C for up to 3 months. Reconstituted research-grade peptide: use within 7–14 days when refrigerated at 2–8°C.